



ATTORNEY DOCKET NO. CSHL.005.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re application of: Malinow *et al.*

)
) Examiner: S. L. Turner

AUG 02 2001

Serial No.: 09/353,126

)
) Art Unit: 1647

TECH CENTER 1600/290A

Filed: July 14, 1999

For: Diagnostic methods for drug screening for
Alzheimer's disease

) REQUEST FOR WITHDRAWAL
) OF FINALITY

Assistant Commissioner For Patents
Washington, D.C. 20231

Sir:

Applicants are in receipt of the Final Rejection dated May 9, 2001, and hereby request
withdrawal of the finality of the Office action (paper no. 6).

REMARKS

The Examiner has provided new grounds for rejection of Claims 1 and 3-13 under 35
U.S.C. § 112, first paragraph, written description. Specifically, claims 1 and 3-13 were
rejected because "the claims recite a 'presenilin gene mutation', however no "gene" is
described". This is the first instance in which a written description rejection of these claims
has been cited.

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this paper or fee is being deposited
with the United States Postal Service as first class mail
in an envelope addressed to the Assistant
Commissioner For Patents, Washington, D.C. 20231 on
Date: July 25, 2001

Signature: [Signature]

Printed Name: Jeffrey M Libby